Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Osteoporosis
Published in: Archives of Osteoporosis 1/2021

01-12-2021 | Bisphosphonate | Review

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)

Authors: Rosa M. R. Pereira, Mariana O. Perez, Ana Patrícia Paula, Caio Moreira, Charlles H. M. Castro, Cristiano A. F. Zerbini, Diogo S. Domiciano, Elaine de Azevedo, Laura M. C. Mendonca, Marcia Midore Shinzato, Marco Antonio A. da Rocha-Loures, Sebastião Radominski, Vera L. Szejnfeld

Published in: Archives of Osteoporosis | Issue 1/2021

Login to get access

Abstract

Summary

The Brazilian guidelines for prevention and treatment of glucocorticoid-induced osteoporosis were updated and important topics were included such as assessment of risk fracture using FRAX Brazil, use of denosumab, and also recommendations for the use of glucocorticoid pulse therapy and inhaled glucocortiocoid.

Introduction

Glucocorticoids (GCs) are used in almost all medical specialties and the incidences of vertebral/nonvertebral fractures range from 30 to 50% in individuals treated with GCs for over 3 months. Thus, osteoporosis and frailty fractures should be prevented and treated in patients initiating treatment or already being treated with GCs. The Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology (BSR) established in 2012 the Brazilian Guidelines for glucocorticoid-induced osteoporosis (GIO). Herein, we provide a comprehensive update of the original guidelines based on improved available scientific evidence and/or expert experience.

Methods

From March to June 2020, the Osteoporosis Committee of the BRS had meetings to update the questions presented in the first consensus (2012). Thus, twenty-six questions considered essential for the preparation of the recommendations were selected. A systematic literature review based on real-life scenarios was undertaken to answer the proposed questions. The MEDLINE, EMBASE, and SCOPUS databases were searched using specific search keywords.

Results

Based on the review and expert opinion, the recommendations were updated for each of the 26 questions. We included 48 new bibliographic references that became available after the date of the publication of the first version of the consensus.

Conclusion

We updated the Brazilian guidelines for the prevention/treatment of GIO. New topics were added in this update, such as the assessment of risk fracture using FRAX Brazil, the use of denosumab, and approaches for the treatment of children and adolescents. Furthermore, we included recommendations for the use of inhaled GCs and GC pulse therapy in clinical settings.
Literature
1.
Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313(7053):344–346PubMedPubMedCentralCrossRef
2.
van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13(10):777–787PubMedCrossRef
3.
Kaji H, Yamauchi M, Chihara K, Sugimoto T (2006) The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 53(1):27–34PubMedCrossRef
4.
Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48(11):3224–3229PubMedCrossRef
5.
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2005) Use of oral corticosteroids and risk of fractures. June, 2000. J Bone Miner Res 20(8):1487–1494PubMed
6.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Care Res (Hoboken) 69(8):1095–1110CrossRef
7.
Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, Takkouche B, FitzGerald JM (2008) Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf 31(5):409–414PubMedCrossRef
8.
Gonzalez AV, Coulombe J, Ernst P, Suissa S (2018) Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture. Chest 153(2):321–328PubMedCrossRef
9.
Buckley L, Greenwald M, Hochberg M, Lane N, Lindsey S, Paget S, Saag K, Simon L (2001) Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis: 2001 update American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44(7):1496–1503
10.
Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, Bijlsma JW (2004) Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 63(3):324–325PubMedPubMedCentralCrossRef
11.
12.
Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17(1):8–19PubMedCrossRef
13.
Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y, The Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis (2005) Guidelines on the management and treatment of glucocorticoid induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23(2):105–109PubMedCrossRef
14.
Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62(11):1515–1526CrossRef
15.
Pereira RM, Carvalho JF, Paula AP, Zerbini C, Domiciano DS, Gonçalves H, Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology; Brazilian Medical Association; Brazilian Association of Physical Medicine and Rehabilitation et al (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52(4):580–593PubMedCrossRef
16.
17.
Muir JM, Ye C, Bhandari M, Adachi JD, Thabane L (2013) The effect of regular physical activity on bone mineral density in post-menopausal women aged 75 and over: a retrospective analysis from the Canadian multicentre osteoporosis study. BMC Musculoskelet Disord 14:253–261PubMedPubMedCentralCrossRef
18.
El-Khoury F, Cassou B, Latouche A, Aegerter P, Charles M-A, Dargent-Molina P (2015) Effectiveness of two year balance training programme on prevention of fall induced injuries in at risk women aged 75-85 living in community: Ossébo randomised controlled trial. BMJ 351:h3830PubMedPubMedCentralCrossRef
19.
Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36(8):1705–1714PubMedCrossRef
20.
Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN (2012) Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int 23(3):1083–1090PubMedCrossRef
21.
Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28(6):1355–1368PubMedCrossRef
22.
Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6(6):445–454PubMedCrossRef
23.
Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF (2019) Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheum 71(7):1174–1184CrossRef
24.
Rooney M, Bishop N, Davidson J, Beresford MW, Pilkington C, Donagh JM, Wyatt S, Gardner-Medwin J, Satyapal R, Clinch J, Foster H, Elliott M, Verghis R, British Society for Paediatric and Adolescent Rheumatology UK (2019) The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. EClinicalMedicine 12:79–87PubMedPubMedCentralCrossRef
25.
Scanlon PD, Connett JE, Wise RA, Tashkin DP, Madhok T, Skeans M, Carpenter PC, Bailey WC, Buist AS, Eichenhorn M, Kanner RE, Weinmann G, Lung Health Study Research Group (2004) Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 170(12):1302–1309PubMedCrossRef
26.
Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B (2009) Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 136(6):1456–1465PubMedCrossRef
27.
Zhao R, Zhang M, Zhang Q (2017) The Effectiveness of Combined Exercise Interventions for Preventing Postmenopausal Bone Loss: A Systematic Review and Meta-analysis. J Orthop Sports Phys Ther 47(4):241–251PubMedCrossRef
28.
Chow TH, Lee BY, Ang ABF, Cheung VYK, Ho MMC, Takemura S (2017) The effect of Chinese martial arts Tai Chi Chuan on prevention of osteoporosis: A systematic review. J Orthop Translat 12:74–84PubMedPubMedCentralCrossRef
29.
Yanbeiy ZA, Hansen KE (2019) Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther 13:2843–2852PubMedPubMedCentralCrossRef
30.
Hansen KE, Kleker B, Safdar N, Bartels CM (2014) A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum 44(1):47–54PubMedPubMedCentralCrossRef
31.
Smits NA, Duru N, Bijlsma JW, Jacobs JW (2011) Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis. Clin Exp Rheumatol 29(5 Suppl 68):S85–S92PubMed
32.
Lau EM, Woo J, Chan YH, Li M (2001) Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 29(6):506–510PubMedCrossRef
33.
Zerbini CA, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 10:224PubMedCrossRef
34.
Seo S, Chun S, Newell MA, Yun M (2015) Association between alcohol consumption and Koeran young women´s bone health: cross-sectional study from the 2008 to 2011 Korea National Health and Nutritional Examination Survey. BMJ Open 5:e007914PubMedPubMedCentralCrossRef
35.
De Vries OJ, Peeters GMEE, Lips P, Deeg DJH (2013) Does frailty predict increased risk of falls and fractures? A prospective population-based study. Osteoporos Int 24(9):2397–2403PubMedCrossRef
36.
Langsetmo L, Barr SI, Berger C, Kreiger N, Rahme E, Adachi JD et al (2015) Associations of protein intake and protein source with bone mineral density and fracture risk: a population-based cohort study. J Nutr Health Aging 19(8):861–868PubMedPubMedCentralCrossRef
37.
Madureira MM, Takayama L, Gallinaro AL, Caparbo VF, Costa RA, Pereira RM (2007) Balance training program is highly effective in improving functional status and reducing the risk of falls in elderly women with osteoporosis: a randomized controlled trial. Osteoporos Int 18(40):419–425PubMedCrossRef
38.
Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC (2008) Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 359(13):1410–1411PubMedCrossRef
39.
Almehed K, Hetenyi S, Ohlsson C, Carlsten H, Forsbladd’Elia H (2010) Prevalence and risk factors of vertebral compression fractures in female SLE patients. Arthritis Res Ther 12(4):R153PubMedPubMedCentralCrossRef
40.
Green SB, Pappas AL (2014) Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm 71(23):2029–2036PubMedCrossRef
41.
French AE, Kaplan N, Lishner M, Koren G (2003) Taking bisphosphonates during pregnancy. Can Fam Physician 49:1281–1282PubMedPubMedCentral
42.
Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis GG, Papaioannou NA, Tournis S (2011) The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 10(4):280–291CrossRef
43.
Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32(4):426–438PubMedCrossRef
44.
Kageyama G, Okano T, Yamamoto Y, Nishimura K, Sugiyama D, Saegusa J, Tsuji G, Kumagai S, Morinobu A (2017) Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study. Bone Rep 6:3–8PubMedCrossRef
45.
Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G (2015) Comparison of high versus low-medium prednisone doses for the treatment of systemic lupuserythematosus patients with high activity at diagnosis. Autoimmun Rev 14(10):875–879PubMedCrossRef
46.
Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS (2001) Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345(13):941–947PubMedCrossRef
47.
Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R et al (2000) Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 355(9213):1399–1403PubMedCrossRef
48.
Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE (2002) Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 166(12 Pt 1):1563–1566PubMedCrossRef
49.
Kasayama S, Fujita M, Goya K, Yamamoto H, Fujita K, Morimoto Y, Kawase I, Miyatake A (2005) Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. Metabolism 54(1):85–90PubMedCrossRef
50.
Ward LM, Rauch F (2018) Anabolic Therapy for the Treatment of Osteoporosis in Childhood. Curr Osteoporos Rep 16(3):269–276PubMedCrossRef
51.
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12(1):43PubMedPubMedCentralCrossRef
52.
Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:190513CrossRef
53.
Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Buchon D, Debiais F, Guggenbuhl P, Laroche M, Legrand E, Lespessailles E, Marcelli C, Weryha G, Thomas T, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 81(6):493–501PubMedCrossRef
54.
Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA (2019) Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom 22(4):453–471PubMedCrossRef
55.
Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N, International Society of Clinical Densitometry (2014) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 17(2):275–280PubMedCrossRef
56.
Bianchi ML, Leonard MB, Bechtold S, Högler W, Mughal MZ, Schönau E, Sylvester FA, Vogiatzi M, van den Heuvel-Eibrink M, Ward L, International Society for Clinical Densitometry (2014) Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD Pediatric Official Positions. J Clin Densitom 17(2):281–294PubMedCrossRef
57.
Roth J, Bechtold S, Borte G, Dressler F, Girschick H, Borte M (2007) Diagnosis, prophylaxis and therapy of osteoporosis in juvenile idiopathic arthritis: consensus statement of the German Association for Pediatric Rheumatology. Z Rheumatol 66(5):434–440PubMedCrossRef
58.
Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, Jefferies C, Hofman PL, Jensen DE, Woodhead H, Brown J, Wheeler BJ, Brookes D, Lafferty A, Munns CF, on behalf of the APEG Bone Mineral Working Group (2018) APEG Bone Mineral Working Group. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 54(3):223–233PubMedCrossRef
59.
Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Köhler L, van Riel P, Vischer T, Bijlsma JW (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61(8):718–722PubMedPubMedCentralCrossRef
60.
Sambrook P, Birmingham J, Kelly P, Kempler S, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 328(24):1747–1752PubMedCrossRef
61.
Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah I et al (2008) A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol 35(12):2344–2347PubMedCrossRef
62.
Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 125(12):961–968PubMedCrossRef
63.
Jensen J, Christiansen C, Rødbro P (1985) Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 313(16):973–975PubMedCrossRef
64.
de Jong Z, Munneke M, Lems WF, Zwinderman AH, Kroon HM, Pauwels EK et al (2004) Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 50(4):1066–1076PubMedCrossRef
65.
Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242–247PubMedCrossRef
66.
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG, Lane N, Correa-Rotter R, Yanover M, Westhovens R, Epstein S, Adachi JD, Poubelle P, Melo-Gomes J, Rodriguez-Portales JA (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339(5):292–299PubMedCrossRef
67.
Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42(11):2309–2318PubMedCrossRef
68.
de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355(7):675–684PubMedCrossRef
69.
Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67(4):277–285PubMedCrossRef
70.
Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PEE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MOR, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44(1):202–211PubMedCrossRef
71.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRef
72.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373(9671):1253–1263CrossRef
73.
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028–2039PubMedCrossRef
74.
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346–3355PubMedCrossRef
75.
Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20(12):2095–2104PubMedCrossRef
76.
Winzenberg T, Oldenburg B, Frendin S, De Wit L, Riley M, Jones G (2006) The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260]. BMC Public Health 6(12):1–12
77.
Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35(11):2249–2254PubMedCrossRef
78.
Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44(3):428–430PubMedCrossRef
79.
Brown JJ, Zacharin MR (2005) Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 41(11):580–582PubMedCrossRef
80.
Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15(4):301–310PubMedCrossRef
81.
de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15(8):589–602PubMedCrossRef
82.
Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD000952
83.
Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39(2):253–259PubMedCrossRef
84.
Cruse LM, Valeriano J, Vasey FB, Carter JD (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12(5):221–225PubMedCrossRef
85.
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of Oral Corticosteroids and Risk of Fracture. J Bone Miner Res 15(6):993–1000PubMedCrossRef
86.
van Staa TP, Cooper C, Leufkens HG, Bishop N (2003) Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18(5):913–918PubMedCrossRef
87.
Blodgett FM, Burgin L, Iezzoni D, Gribetz D, Talbot NB (1956) Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children. N Engl J Med 254(14):636–641PubMedCrossRef
88.
Varonos S, Ansell BM, Reeve J (1978) Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int 41(2):75–78CrossRef
89.
Rietbrock S, Olson M, van Staa TP (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102(1):35–42PubMedCrossRef
90.
Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A (1999) Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60(2):68–73PubMedCrossRef
91.
Minsker DH, Manson JM, Peter CP (1993) Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121(2):217–223PubMedCrossRef
92.
Chan B, Zacharin M (2006) Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91(6):2017–2020PubMedCrossRef
93.
Munns CF, Rauch F, Ward L, Glorieux FH (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19(10):1742–1745PubMedCrossRef
94.
Yarrington JT, Capen CC, Black HE, Re R, Potts JT Jr, Geho WB (1976) Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion. Am J Pathol 83(3):569–588PubMedPubMedCentral
95.
Pongchaiyakul C, Nguyen TV, Kosulwat V, Rojroongwasinkul N, Charoenkiatkul S, Eisman JA, Rajatanavin R (2004) Effects of physical activity and dietary calcium intake on bone mineral density and osteoporosis risk in a rural Thai population. Osteoporos Int 15(10):807–813PubMedCrossRef
96.
Morin S, Tsang JF, Leslie WD (2009) Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int 20(3):363–370PubMedCrossRef
97.
Schmitt NM, Schmitt J, Dören M (2009) The role of physical activity in the prevention of osteoporosis in postmenopausal women. An update. Maturitas 63(1):34–38PubMedCrossRef
98.
Canalis E, Giustina A, Bilezikian IP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(9):905–916PubMedCrossRef
99.
Maricic M, Gluck O (2004) Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom 7(4):359–363PubMedCrossRef
100.
Franchimont N, Canalis E (2003) Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev 2(4):224–228PubMedCrossRef
Metadata
Title
Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)
Authors
Rosa M. R. Pereira
Mariana O. Perez
Ana Patrícia Paula
Caio Moreira
Charlles H. M. Castro
Cristiano A. F. Zerbini
Diogo S. Domiciano
Elaine de Azevedo
Laura M. C. Mendonca
Marcia Midore Shinzato
Marco Antonio A. da Rocha-Loures
Sebastião Radominski
Vera L. Szejnfeld
Publication date
01-12-2021
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2021
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-021-00902-z

Other articles of this Issue 1/2021

Archives of Osteoporosis 1/2021 Go to the issue

Original Article

Osteoporosis treatment rate following hip fracture in a community hospital

Original Article

Nonoperative hip fracture management practices and patient survival compared to surgical care: an analysis of Estonian population-wide data

Original Article

Assessing the roles of demographic, social, economic, environmental, health-related, and political factors on risk of osteoporosis diagnosis among older adults

Original Article

Cortical bone thickness predicts the quantitative bone mineral density of the proximal humerus

Original Article

Association between geriatric nutrition risk index and bone mineral density in elderly Chinese people

Original Article

Impact of paravertebral muscle in thoracolumbar and lower lumbar regions on outcomes following osteoporotic vertebral fracture: a multicenter cohort study